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A 24 h pretreatment of MRCS fibroblasts with the protein kinase C activator 12-O-tetradecanoylphorbol 
13-acetate (TPA) induced a marked decrease in low density lipoprotein (LDL) internalization and degrada- 
tion; the maximal effect (about 55% decrease) was observed for 10m7 M TPA. LDL binding was reduced 
about 35-40s. A significant decrease (about 25%) in LDL internalization was observed after a 2 h incuba- 
tion of cells with the drug, but longer incubation times (46 h) led to a greater effect. Another tumor promot- 
er, phorbol 12,13-dibutyrate decreased LDL internalization by about 35 s;, whereas the non-tumor promot- 
ing 4cr-phorbol 12,13-didecanoate had no effect. The protein kinase C inhibitor a-cobrotoxin partially antag- 
onized the inhibitory effect of TPA on LDL internalization. The non-phorbol tumor promoter mezerein, 
another protein kinase C activator, decreased LDL uptake by about 50%. Finally, it was found that TPA 
had no significant effect on the affinity of the receptor for the LDL. These results suggest a role for protein 
kinase C in the LDL pathway in cultured human fibroblasts. 
LDL Phorbol ester Protein kinase C (Humanjbroblast) 
1. INTRODUCTION 
LDL catabolism is mainly achieved by a 
receptor-mediated endocytic pathway, which 
results in down-regulation of sterol metabolism 
[ 1,2]. In previous studies, we demonstrated a 
significant decrease in LDL internalization in 
cultured human fibroblasts pretreated with the 
calcium ionophore A23 187, which suggested a role 
for Ca’+ in the control of LDL endocytosis [3]. 
Several reports pointed out the synergy between 
Ca2+ and protein kinase C activation in various 
cellular processes such as steroidogenesis [4], 
histamine release from mast cells [5] or insulin 
secretion [6]. Tumor-promoting phorbol esters, 
which activate protein kinase C [7,8], have been 
demonstrated to inhibit epidermal growth factor 
Abbreviations: TPA, 12-0-tetradecanoyl phorbol 
13-acetate; PDBu, phorbol 12,13_dibutyrate; (Y-PDD, 
4cu-phorbol 12,13-didecanoate; LDL, low density 
lipoprotein 
[9, lo] or insulin binding [ 111. More recently, Rouis 
et al. [ 121 reported that phorbol esters inhibit LDL 
processing in the monocyte-like cell strain U 937. 
In contrast, Shoyab et al. [13] found no effect of 
phorbol esters on LDL binding by cultured human 
fibroblasts. In this study, we re-examined the ef- 
fects of various phorbol esters on LDL processing 
by cultured human fibroblasts, and found that 
tumor-promoting phorbol esters significantly 
reduced LDL binding and markedly inhibited LDL 
internalization. Non-tumor-promoting phorbol 
esters had no effect. 
2. MATERIALS AND METHODS 
2.1. Reagents 
TPA, PDBu, a-PDD, mezerein and cy- 
cobrotoxin were from Sigma. 
2.2. Cell culture 
MRCS (human foetal lung fibroblasts) were pur- 
chased from Biomerieux and kept in Ham FlO 
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medium supplemented with 10% foetal calf serum In experiments designed to determine whether 
(Gibco) in 75 cm* Falcon flasks at 37”C, in a 5% the receptor number or the affinity is reduced, cells 
CO2 humidified atmosphere. For experiments, were incubated with increasing concentrations of 
cells were grown in 30 mm petri dishes (Nunc) in ‘*‘I-LDL (1.25-50pg/ml) in the absence or 
Ham FlO medium supplemented with 2% Ultroser presence of 500 pg/ml unlabelled LDL. After a 2 h 
G (Industries Biologiques Francaises) and effecters incubation at 4”C, the radioactivity associated 
as specified below. with the cells was measured as described above. 
2.3. LDL preparation and labelling 
LDL was prepared from normal human serum 
according to Have1 et al. [14] and labelled as 
described in [ 151, using Na’251 (Amersham, 
13-17 Ci/mg). The specific activity of the LDL 
was about 200-300 dpm/ng protein. Protein 
determination was done according to Lowry et al. 
1161. 
3. RESULTS AND DISCUSSION 
2.4. Effect of phorbol esters, mezerein and 
a-cobrotoxin on LDL binding, 
internalization and degradation 
Cells were incubated for 2-24 h in Ham FlO 
medium + 2% Ultroser G in the absence or 
presence of different protein kinase C effecters 
(phorbol esters, mezerein, a-cobrotoxin) at the in- 
dicated concentrations. After preincubation, the 
cells were washed 3 times with a phosphate- 
buffered solution, and then LDL binding, inter- 
nalization and degradation were studied according 
to Goldstein and Brown [ 11. Incubations were per- 
formed for 2 h at 4°C for binding studies, and 4 h 
at 37°C for uptake and degradation studies, in 
0.5 ml Ham FlO, 10 mM Hepes (pH 7.4) medium. 
The final concentration of LDL in the incubation 
medium was lOpg/ml. After incubation, cells 
were washed 4 times with a phosphate-buffered 
solution (pH 7.4), harvested with a rubber 
policeman and centrifuged for 5 min at 400 x g. 
The radioactivity associated with the pellet was 
measured with a Packard 256 gamma counter. For 
the study of ‘251-LDL degradation, the incubation 
medium (0.5 ml) was removed before cell washing 
and 0.25 ml of 1% bovine serum albumin + 
0.25 ml of 50% t;ichloroacetic acid were added. 
The precipitate was centrifuged for 10 min at 4000 
x g. 0.01 ml of 40% KI and 0.05 ml of 30% Hz02 
were then added to 0.5 ml of the supernatant. 
After mixing, the samples were maintained for 
30 min at 4”C, then extracted with 2 ml 
chloroform and the radioactivity counted on 
0.2 ml of the upper phase. 
Fig.1 displays the effect of the protein kinase C 
activator TPA on LDL binding, uptake and 
degradation in relation to the drug concentration. 
A dose-dependent decrease was observed, with a 
maximal reduction of about 35-40% of LDL 
binding, and 50-60% decrease in LDL uptake and 
degradation for lo-’ M TPA. 
In the following experiments, we studied 
especially the effect of protein kinase C effecters 
on LDL internalization and degradation. 
It can be seen in fig.2 that a small effect was ob- 
tained for an incubation time as short as 2 h (about 
6 7 6. _ 
-log TPA CM) 
Fig. 1. Effect of TPA on LDL binding (0), 
internalization (v) and degradation (v) by MRCS 
human fibroblasts, in relation to drug concentration. 
Cells were preincubated 24 h with TPA in Ham FlO 
medium supplemented with 2% Ultroser G, washed 3 
times and then LDL binding, internalization and 
degradation were determined as described in section 2 
with iz51-LDL (10 /g/ml). Results are expressed in % of 
controls (100%: 134 f 22 ng LDL bound, 570 f 96 ng 
LDL internalized and 1368 f 232 LDL degraded per mg 
cell protein); mean of 3 experimental values. 
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Fig.2. Effect of 5 x lo-’ M TPA on LDL internalization 
by MRCS fibroblasts in relation to the preincubation 
time of cells with the drug. Preincubation was 
performed in Ham FlO medium supplemented with 2% 
Ultroser G. Cells were then washed and LDL 
internalization was measured as described in section 2 
with “‘1-LDL (10 fig/ml). Results are expressed in 070 of 
controls (100%: 579 f 96 ng LDL internalized); mean of 
3 or 4 experimental values. 
25% decrease), but a longer incubation time led to 
a greater reduction in LDL uptake. 80% of the 
maximal effect was obtained within 6 h of prein- 
cubation in the presence of lo-’ M TPA. 
To study the relationship between the tumor- 
promoting activity of drugs and their effect on 
LDL processing by MRCS fibroblasts, we com- 
pared various tumor and non-tumor promoters for 
their capacity to reduce LDL uptake and degrada- 
tion: TPA and PDBu, which are tumor-promoting 
phorbol esters shown to activate protein kinase C; 
wPDD, which has no tumor-promoting effect, 
and does not activate protein kinase C; and 
mezerein, a non-phorbol tumor promoter which 
has recently been reported to activate strongly pro- 
tein kinase [17]. The effect of cobrotoxin, a potent 
inhibitor of protein kinase C [ 181, has also been in- 
vestigated. The results of these studies are sum- 
marized in table 1. 
It can be observed that the tumor-promoting 
protein kinase C activator PDBu was almost as ef- 
fective as TPA in reducing LDL processing by 
MRCS fibroblasts (about 40% decrease was ob- 
tained with PDBu lo-’ M). In contrast, wPDD 
had no significant effect on LDL uptake and 
degradation. The non-phorbol tumor promoter 
and protein kinase C activator mezerein reduced 
LDL uptake and degradation to about 50% of 
controls at 10m6 M. Finally, the protein kinase C 
inhibitor cobrotoxin alone slightly stimulated LDL 
internalization and degradation, and antagonized 
the inhibitory effect of TPA when cells were 
pretreated simultaneously with these drugs. 
Experiments were then performed to determine 
Table 1 
Effect of various phorbol esters (TPA, PDBu, wPDD) and non-phorbol protein kinase C effecters 
(mezerein, activator; cobrotoxin, inhibitor) on LDL internalization and degradation by MRCS 
human fibroblasts 
Addition 
None 
TPA (lo-’ M) 
PDBu (lo-’ M) 
(r-PDD (IO-’ M) 
Cobrotoxin (50 rg/ml) 
Internalization 
(ng/mg protein) 
570 f 96 (100%) 
268 f 38 ( 47%) 
331 + 50 ( 58%) 
558 f 78 ( 98%) 
Degradation 
(ng/mg protein) 
1368 f 232 (100%) 
616 f 92 ( 45%) 
862 f 134 ( 63%) 
1310 f 225 ( 96%) 
TPA (lo-’ M) + cobrotoxin (50 #g/ml) 
706 + 122 (124%) 1532 * 245 (112%) 
421 f 65 ( 74%) 
Mezerein (10m6 M) 
985 f 167 ( 72%) 
296 f 46 ( 52%) 656 f 92 ( 48%) 
Cells were preincubated for 24 h with the drugs at the indicated concentrations in Ham FlO medium 
supplemented with 2% Ultroser G, and then were washed 3 times before LDL internalization and 
degradation were measured with “‘1-LDL (lOpg/ml). Results are mean of 3 experimental 
values + SD 
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if the number of receptors was reduced by TPA or metabolism in skin and MRCS fibroblasts. It must 
if the affinity of the receptor for the LDL was af- be also emphasized that the experimental condi- 
fected. Linearization plot of the data according to tions were notably different; in our experiments 
Riggs [19] showed (fig.3) that the K,,, (point of in- cells were incubated with TPA in Ham FlO 
tersection with the y axis = -Km) was not medium devoid of lipoproteins, whereas in 
significantly modified under 5 x lo-’ M TPA Shoyab’s experiments it seems that cells were 
(about 6pM with or without TPA). In contrast, grown in Dulbecco’s medium supplemented with 
the I’,,,,, was about 40-45% reduced in treated 10% foetal calf serum. In the latter experimental 
cells as compared to untreated cells (7.5 ng LDL conditions, fibroblasts exhibit a very low level of 
bound/,ug of cell protein in the presence of TPA, LDL receptors (about 15-20070 as compared to the 
and 13 ng/pg in controls). Thus, the number of number of receptors of cells maintained in a 
LDL receptors at the cell surface appears to be medium devoid of lipoproteins). In this case, it 
decreased without any significant modification of may be difficult to point out a reduction in LDL 
their affinity for the lipoprotein. uptake by TPA. 
Our results demonstrate that the tumor- 
promoting phorbol esters TPA and PDBu 
significantly inhibit LDL processing by MRCS 
fibroblasts. This effect appears to be probably 
related to the activating effect of these drugs on 
protein kinase C activity, as the non-phorbol pro- 
tein kinase C activator mezerein was also effective. 
These results are not in accordance with those of 
Shoyab et al. [13], who found no effect of TPA on 
LDL binding by foreskin fibroblasts. It must be 
considered that the effect of TPA may be depen- 
dent on the cell strain, although we generally 
observed similar regulation of LDL and sterol 
Our findings may be compared to those of Rouis 
et al. [12] who recently pointed out a decrease in 
LDL binding by TPA in a different system; the 
monocyte-like strain U 937. However, there are 
marked differences in the kinetics of TPA effect in 
fibroblasts and in the monocyte-like strain U 937. 
In the U 937 strain, the maximal effect of TPA 
was obtained for very short preincubation times of 
cells with the drug (less than 1 h), whereas we only 
observed a half-maximal effect (about 25% reduc- 
tion) for a 2 h preincubation of fibroblasts with 
TPA. A 4-6 h incubation time is necessary to ob- 
tain the maximal effect (55% reduction) in 
fibroblasts. 
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Fig.3. Effect of 5 x 10m5 M TPA on the affinity of 
receptors for LDL. After a 24 h preincubation with 5 x 
10m5 M TPA, cells were washed, then incubated for 2 h 
at 4°C with increasing ‘?-LDL concentrations 
(1.25-50 pg/ml) in the absence or presence of 500 @g/ml 
unlabelled LDL. (0) Controls, (0) 5 x lo-’ M TPA. 
Linearization plot of the data was done according to 
Riggs [19]. Each point is the mean of 3 experimental 
values. Intersection with y axis = -Km; slope = I’,,,. 
The mechanism whereby tumor-promoting 
phorbol esters inhibit LDL uptake by fibroblasts is 
still unknown. The fact that mezerein, another 
protein kinase C activator, mimics the effect of 
TPA, suggests that protein kinase C is involved in 
the phenomenon. This hypothesis is further sup- 
ported by the ability of cobrotoxin, a protein 
kinase C inhibitor [18], to antagonize the TPA- 
induced reduction of LDL uptake. Rouis et al. [12] 
suggested that TPA could induce phosphorylation 
of the receptor and the formation of a cryptic 
pool, by inhibition of receptor recycling. In fact, 
LDL receptor recycling is very rapid: about 9 min 
per cycle as described by Anderson et al. [20]. 
Thus, the inhibition of the LDL receptor recycling 
is compatible with the rapid effect of TPA de- 
scribed by Rouis et al. [12] in the U 937 strain, 
since these authors found significant inhibition of 
LDL binding for a preincubation time as short as 
15 min. In our case, the absence of effect of TPA 
under 1 h suggests that other mechanisms may be 
involved in fibroblasts. 
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In conclusion, our findings point out an in- 
hibitory effect of phorbol and non-phorbol protein 
kinase C activators on LDL processing by human 
fibroblasts. This suggests a role for protein kinase 
C in the control of receptor-mediated LDL en- 
docytosis in these cells. 
Experiments are now being performed to 
elucidate the actual mechanism of the inhibition of 
LDL uptake by phorbol esters and mezerein in 
human fibroblasts, especially the determination of 
the state of phosphorylation of the LDL receptor 
under TPA treatment. 
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